ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company based in Burlingame, United States, operates within the health care sector. The company is listed on the Nasdaq stock exchange and trades in USD. As of the close of trading on January 28, 2026, ALX Oncology Holdings Inc. had a share price of $1.57. The company’s market capitalization stands at $75,910,000.
ALX Oncology Holdings Inc. is dedicated to developing therapies that harness the innate and adaptive immune systems to aid patients in their battle against cancer. The company primarily serves patients residing in California. For more detailed information about their activities and offerings, interested parties can visit their official website at www.alxoncology.com .
In terms of financial performance, the company’s stock has experienced significant volatility over the past year. The 52-week high was recorded at $2.27 on October 5, 2025, while the 52-week low was $0.404 on June 26, 2025. As of the latest data release, there have been no new developments reported by the company. The most recent public reference was a transcript from the JPMorgan Healthcare Conference, dated January 16, 2026. At that time, the share closed at $1.37.
Financial metrics for ALX Oncology Holdings Inc. indicate a negative price-to-earnings ratio of -0.7, reflecting the company’s current lack of profitability. Additionally, the price-to-book ratio stands at 1.69431. These figures highlight the speculative nature of the company’s stock, given its clinical stage and the inherent risks associated with the development of new therapies in the immuno-oncology field.
